After CD22 CAR-T, nine patients (39.1%) experienced CRS (grade 1, n = 3; grade 2, n = 6), with a median onset and duration of 1 day (range 1–5) and 5 days (range 3–14), respectively. The gene discussed is CD22; the disease is congenital rubella syndrome.